Enterprise Value

898.6M

Cash

185M

Avg Qtr Burn

N/A

Short % of Float

13.04%

Insider Ownership

4.68%

Institutional Own.

96.35%

Qtr Updated

06/30/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

Approved

Quarterly sales

Vixarelimab (OSMRβ) (KPL-716) Details
Skin disease/disorder, Prurigo nodularis

Phase 2b

Update

KPL-404 (CD40) Details
Autoimmune disease, Rheumatoid arthritis

Phase 2

Data readout

Mavrilimumab (GM-CSFRa) Details
Inflammatory disease, Giant cell arteritis

Failed

Discontinued

Failed

Discontinued